Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

PSMA PET/CT imaging for primary staging of intermediate and high-risk prostate cancer.

Cook GJR, Kulkarni M, Warbey VS.

BJU Int. 2019 Sep;124(3):357-358. doi: 10.1111/bju.14856. No abstract available.

PMID:
31436039
2.

Ga-PSMA PET/CT Staging of Newly Diagnosed Intermediate- and High-Risk Prostate Cancer.

Kuten J, Mabjeesh NJ, Lerman H, Levine C, Barnes S, Even-Sapir E.

Isr Med Assoc J. 2019 Feb;21(2):100-104.

3.

68 Ga-PSMA-PET/CT staging prior to definitive radiation treatment for prostate cancer.

Hruby G, Eade T, Emmett L, Ho B, Hsiao E, Schembri G, Guo L, Kwong C, Hunter J, Byrne K, Kneebone A.

Asia Pac J Clin Oncol. 2018 Aug;14(4):343-346. doi: 10.1111/ajco.12872. Epub 2018 Apr 16.

PMID:
29663686
4.

A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.

Hofman MS, Murphy DG, Williams SG, Nzenza T, Herschtal A, Lourenco RA, Bailey DL, Budd R, Hicks RJ, Francis RJ, Lawrentschuk N.

BJU Int. 2018 Nov;122(5):783-793. doi: 10.1111/bju.14374. Epub 2018 Jun 3.

PMID:
29726071
5.

More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.

Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.

Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.

PMID:
30843003
6.

Comparison of 68Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer.

Zhang Q, Zang S, Zhang C, Fu Y, Lv X, Zhang Q, Deng Y, Zhang C, Luo R, Zhao X, Wang W, Wang F, Guo H.

J Transl Med. 2017 Nov 7;15(1):230. doi: 10.1186/s12967-017-1333-2.

7.

Risk of metastatic disease on 68 gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer.

Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, Yaxley AJ, Gianduzzo T, Kua B, McEwan L, Wong D.

BJU Int. 2019 Sep;124(3):401-407. doi: 10.1111/bju.14828. Epub 2019 Jul 2.

PMID:
31141284
8.

Current status of theranostics in prostate cancer.

Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C.

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):471-495. doi: 10.1007/s00259-017-3882-2. Epub 2017 Dec 28. Review.

9.

68Ga-PSMA PET/CT and Volumetric Morphology of PET-Positive Lymph Nodes Stratified by Tumor Differentiation of Prostate Cancer.

Vinsensia M, Chyoke PL, Hadaschik B, Holland-Letz T, Moltz J, Kopka K, Rauscher I, Mier W, Schwaiger M, Haberkorn U, Mauer T, Kratochwil C, Eiber M, Giesel FL.

J Nucl Med. 2017 Dec;58(12):1949-1955. doi: 10.2967/jnumed.116.185033. Epub 2017 Jun 21.

10.

Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer.

Tulsyan S, Das CJ, Tripathi M, Seth A, Kumar R, Bal C.

Nucl Med Commun. 2017 Dec;38(12):1094-1102. doi: 10.1097/MNM.0000000000000749.

PMID:
28957842
11.

Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.

Haran C, McBean R, Parsons R, Wong D.

J Med Imaging Radiat Oncol. 2019 Aug;63(4):495-499. doi: 10.1111/1754-9485.12885. Epub 2019 Apr 11.

PMID:
30972933
12.

Gallium-68-prostate-specific membrane antigen (68 Ga-PSMA) positron emission tomography (PET)/computed tomography (CT) predicts complete biochemical response from radical prostatectomy and lymph node dissection in intermediate- and high-risk prostate cancer.

van Leeuwen PJ, Donswijk M, Nandurkar R, Stricker P, Ho B, Heijmink S, Wit EMK, Tillier C, van Muilenkom E, Nguyen Q, van der Poel HG, Emmett L.

BJU Int. 2019 Jul;124(1):62-68. doi: 10.1111/bju.14506. Epub 2019 Apr 7.

PMID:
30074667
13.

The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer.

Öbek C, Doğanca T, Demirci E, Ocak M, Kural AR, Yıldırım A, Yücetaş U, Demirdağ Ç, Erdoğan SM, Kabasakal L; Members of Urooncology Association, Turkey.

Eur J Nucl Med Mol Imaging. 2017 Oct;44(11):1806-1812. doi: 10.1007/s00259-017-3752-y. Epub 2017 Jun 18.

PMID:
28624849
14.

The Impact of 68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study.

Roach PJ, Francis R, Emmett L, Hsiao E, Kneebone A, Hruby G, Eade T, Nguyen QA, Thompson BD, Cusick T, McCarthy M, Tang C, Ho B, Stricker PD, Scott AM.

J Nucl Med. 2018 Jan;59(1):82-88. doi: 10.2967/jnumed.117.197160. Epub 2017 Jun 23.

15.

68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.

von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G.

Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15.

16.
17.

68Ga-PSMA-11 PET/CT in Newly Diagnosed Prostate Adenocarcinoma.

Ergül N, Yilmaz Güneş B, Yücetaş U, Toktaş MG, Çermik TF.

Clin Nucl Med. 2018 Dec;43(12):e422-e427. doi: 10.1097/RLU.0000000000002289.

PMID:
30273204
18.

Potential Impact of 68Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate Cancer.

Calais J, Kishan AU, Cao M, Fendler WP, Eiber M, Herrmann K, Ceci F, Reiter RE, Rettig MB, Hegde JV, Shaverdian N, King CR, Steinberg ML, Czernin J, Nickols NG.

J Nucl Med. 2018 Nov;59(11):1714-1721. doi: 10.2967/jnumed.118.209387. Epub 2018 Apr 13.

19.

Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130 Consecutive Patients with Intermediate to High Risk Prostate Cancer.

Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kübler H, Beer AJ, Schwaiger M, Eiber M.

J Urol. 2016 May;195(5):1436-1443. doi: 10.1016/j.juro.2015.12.025. Epub 2015 Dec 9.

PMID:
26682756
20.

Advances in prostate-specific membrane antigen PET of prostate cancer.

Bouchelouche K, Choyke PL.

Curr Opin Oncol. 2018 May;30(3):189-196. doi: 10.1097/CCO.0000000000000439. Review.

Supplemental Content

Support Center